Advertisement

Topics

CSL’s Hizentra Meets Primary Endpoint in Phase 3 Study in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

10:52 EST 10 Nov 2017 | Speciality Pharma Journal

KING OF PRUSSIA, Pa., Nov. 9, 2017 /PRNewswire/ — Global biotherapeutics leader CSL Behring announced that results were published in The Lancet Neurology from its PATH study (Polyneuropathy And Treatment with Hizentra®), a pivotal Phase III study evaluating the safety, efficacy and tolerability of Hizentra (Immune Globulin Subcutaneous [Human] 20% liquid) compared to placebo as …

Original Article: CSL’s Hizentra Meets Primary Endpoint in Phase 3 Study in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

NEXT ARTICLE

More From BioPortfolio on "CSL’s Hizentra Meets Primary Endpoint in Phase 3 Study in Patients with Chronic Inflammatory Demyelinating Polyneuropathy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...